A year in review: NeuroPace Inc (NPCE)’s performance in the last year

While NeuroPace Inc has overperformed by 1.54%%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NPCE fell by -5.54%, with highs and lows ranging from $18.98 to $5.45, whereas the simple moving average fell by -2.26% in the last 200 days.

On May 28, 2025, H.C. Wainwright started tracking NeuroPace Inc (NASDAQ: NPCE) recommending Buy. A report published by UBS on January 21, 2025, Initiated its previous ‘Buy’ rating for NPCE. Wells Fargo also Upgraded NPCE shares as ‘Overweight’, setting a target price of $20 on the company’s shares in a report dated March 14, 2024. Leerink Partners Initiated an Outperform rating on January 30, 2024, and assigned a price target of $22. Cantor Fitzgerald initiated its ‘Overweight’ rating for NPCE, as published in its report on November 10, 2023. Morgan Stanley’s report from August 24, 2023 suggests a price prediction of $6 for NPCE shares, giving the stock a ‘Equal-Weight’ rating. Lake Street also rated the stock as ‘Buy’.

Analysis of NeuroPace Inc (NPCE)

Further, the quarter-over-quarter increase in sales is 24.28%, showing a positive trend in the upcoming months.

NeuroPace Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -128.49% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.70, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.

The average volume for any stock is also a very valuable indicator of volatility, and NPCE has an average volume of 298.88K. On a monthly basis, the volatility of the stock is set at 7.82%, whereas on a weekly basis, it is put at 1.89%, with a loss of -4.52% over the past seven days. Furthermore, long-term investors anticipate a median target price of $17.12, showing growth from the present price of $10.57, which can serve as yet another indication of whether NPCE is worth investing in or should be passed over.

How Do You Analyze NeuroPace Inc Shares?

In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 30.42%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 61.07% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.

NPCE shares are owned by institutional investors to the tune of 61.07% at present.

Hot this week

What to expect from EXK’s earnings report this quarter?

In the current trading session, Endeavour Silver Corp's (EXK)...

Predicting Futu Holdings Ltd ADR’s (FUTU) earnings for the current quarter

Futu Holdings Ltd ADR (FUTU)'s stock is trading at...

NAK’s Q2 earnings predictions: What the experts say

Northern Dynasty Minerals Ltd (NAK)'s stock has witnessed a...

How will Leap Therapeutics Inc’s (LPTX) earnings compare to estimates this quarter?

Currently, Leap Therapeutics Inc's (LPTX) stock is trading at...

ENVX’s Q2 earnings estimates: What investors need to know

In the current trading session, Enovix Corporation's (ENVX) stock...

Topics

What to expect from EXK’s earnings report this quarter?

In the current trading session, Endeavour Silver Corp's (EXK)...

Predicting Futu Holdings Ltd ADR’s (FUTU) earnings for the current quarter

Futu Holdings Ltd ADR (FUTU)'s stock is trading at...

NAK’s Q2 earnings predictions: What the experts say

Northern Dynasty Minerals Ltd (NAK)'s stock has witnessed a...

How will Leap Therapeutics Inc’s (LPTX) earnings compare to estimates this quarter?

Currently, Leap Therapeutics Inc's (LPTX) stock is trading at...

ENVX’s Q2 earnings estimates: What investors need to know

In the current trading session, Enovix Corporation's (ENVX) stock...

Can Webull Corp (BULL) meet market expectations this quarter?

Webull Corp (BULL)'s stock is trading at $10.87 at...

LESL’s earnings forecast for the current quarter

Leslies Inc (LESL)'s stock has witnessed a price hike...

Breaking down LAB’s current quarter earnings estimates

Currently, Standard BioTools Inc's (LAB) stock is trading at...
spot_img

Related Articles

Popular Categories

spot_imgspot_img
US Post News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.